Regenxbio (NASDAQ: RGNX) reported Q2 EPS of ($1.38), $0.44 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $21.36 million versus the consensus estimate of $38.7 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.